IN2014DN05869A - - Google Patents

Info

Publication number
IN2014DN05869A
IN2014DN05869A IN5869DEN2014A IN2014DN05869A IN 2014DN05869 A IN2014DN05869 A IN 2014DN05869A IN 5869DEN2014 A IN5869DEN2014 A IN 5869DEN2014A IN 2014DN05869 A IN2014DN05869 A IN 2014DN05869A
Authority
IN
India
Prior art keywords
tautomer
compounds
pharmaceutically acceptable
acceptable salt
combination
Prior art date
Application number
Inventor
Alejandro Yovine
Matthew Squires
Catherine Reddick
Yong Zhang
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of IN2014DN05869A publication Critical patent/IN2014DN05869A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

A pharmaceutical combination comprising (a) a RTK inhibitor selected from the group consisting of compounds of Formula I or a tautomer thereof compounds of Formula II or a tautomer thereof compounds of Formula III or a tautomer thereof a pharmaceutically acceptable salt of the compound a pharmaceutically acceptable salt of the tautomer or a mixture thereof; and (b) one or more anti estrogen compounds or a pharmaceutically acceptable salt thereof; such as tamoxifen toremifene fulvestrant raloxifene or raloxifene hydrochloride; the uses of such combination in the treatment or prevention of proliferative diseases; and methods of treating a subject suffering from a proliferative disease; and methods of treating a subject suffering from a proliferative disease comprising administering a therapeutically effective amount of such combination.
IN5869DEN2014 2012-01-31 2013-01-30 IN2014DN05869A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261593047P 2012-01-31 2012-01-31
PCT/US2013/023781 WO2013116293A1 (en) 2012-01-31 2013-01-30 Combination of a rtk inhibitor with an anti - estrogen and use thereof for the treatment of cancer

Publications (1)

Publication Number Publication Date
IN2014DN05869A true IN2014DN05869A (en) 2015-05-22

Family

ID=47679114

Family Applications (1)

Application Number Title Priority Date Filing Date
IN5869DEN2014 IN2014DN05869A (en) 2012-01-31 2013-01-30

Country Status (12)

Country Link
US (1) US20140378422A1 (en)
EP (1) EP2809312A1 (en)
JP (1) JP2015505562A (en)
KR (1) KR20140117457A (en)
CN (1) CN104093402A (en)
AU (1) AU2013215251A1 (en)
BR (1) BR112014017985A8 (en)
CA (1) CA2861377A1 (en)
IN (1) IN2014DN05869A (en)
MX (1) MX2014009303A (en)
RU (1) RU2014135436A (en)
WO (1) WO2013116293A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA39741A (en) * 2014-03-13 2017-01-18 Hoffmann La Roche Therapeutic combinations with estrogen receptor modulators
US10118910B2 (en) 2015-12-09 2018-11-06 The Board Of Trustees Of The University Of Illinois Benzothiophene-based selective estrogen receptor downregulators
US11883404B2 (en) 2016-03-04 2024-01-30 Taiho Pharmaceuticals Co., Ltd. Preparation and composition for treatment of malignant tumors
CN110177554B (en) 2017-01-06 2023-06-02 G1治疗公司 Combination therapy for the treatment of cancer
CN110461853A (en) 2017-02-10 2019-11-15 G1治疗公司 Benzothiophene estrogenic agents
SG11202006617RA (en) 2018-01-10 2020-08-28 Eisai R&D Man Co Ltd Combination therapies for the treatment of hepatocellular carcinoma
CA3094431C (en) 2018-03-19 2023-06-27 Taiho Pharmaceutical Co., Ltd. Pharmaceutical composition including sodium alkyl sulfate
EP3777860A4 (en) 2018-03-28 2021-12-15 Eisai R&D Management Co., Ltd. Therapeutic agent for hepatocellular carcinoma
TW202023552A (en) * 2018-09-13 2020-07-01 加拿大商增你智表觀遺傳學公司 Combination therapy for the treatment of estrogen-receptor positive breast cancer
TWI791928B (en) * 2018-11-26 2023-02-11 日商大鵬藥品工業股份有限公司 Method for treating and preventing tumors amenable to endocrine therapy by using fibroblast growth factor receptor inhibitor in combination with endocrine therapy
AU2021315234A1 (en) * 2020-07-31 2023-01-19 Eisai R&D Management Co., Ltd. Therapeutic agent for breast cancer
CN116940363A (en) * 2021-03-03 2023-10-24 正大天晴药业集团股份有限公司 Combination pharmaceutical composition of CDK4/6 inhibitor and application thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE637389A (en) 1962-09-13
US4418068A (en) 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
GB2126576B (en) 1982-06-25 1985-06-19 Farmos Group Limited Alkane and alkene derivatives
GB8327256D0 (en) 1983-10-12 1983-11-16 Ici Plc Steroid derivatives
ATE459616T1 (en) 1998-08-11 2010-03-15 Novartis Ag ISOCHINOLINE DERIVATIVES WITH ANGIOGENESIS-INHIBITING EFFECT
KR100732206B1 (en) 2000-09-11 2007-06-27 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 Quinolinone derivatives as tyrosine kinase inhibitors
US20030028018A1 (en) 2000-09-11 2003-02-06 Chiron Coporation Quinolinone derivatives
ITTV20030095A1 (en) 2003-07-14 2005-01-15 Asolo Spa FOOTWEAR WITH COMPOSITE INSOLE.
TWI347940B (en) 2003-11-07 2011-09-01 Novartis Ag Methods for synthesizing quinolinone compounds
CA2596084A1 (en) * 2005-01-27 2006-08-03 Novartis Vaccines And Diagnostics Inc. Treatment of metastasized tumors with quinolinone benzimidazole compounds
WO2006124413A2 (en) * 2005-05-13 2006-11-23 Novartis Ag Methods for treating drug resistant cancer
EP2266974A1 (en) 2005-05-23 2010-12-29 Novartis AG Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-Quinolin-2-one lactic acid salts
JP2009517481A (en) 2005-11-29 2009-04-30 ノバルティス アクチエンゲゼルシャフト Quinolinone formulation
US20080206194A1 (en) * 2007-02-16 2008-08-28 Glazer Robert I Method for the treatment of breast cancer
PE20091628A1 (en) 2008-03-19 2009-11-19 Novartis Ag CRYSTALLINE FORMS AND TWO SOLVATED FORMS OF LACTIC ACID SALTS OF 4-AMINO-5-FLUORO-3- [5- (4-METHYLPIPERAZIN-1-IL) -1H-BENZIMIDAZOL-2-IL] QUINOLIN-2 (1H) - ONA
AR081776A1 (en) 2010-06-30 2012-10-17 Novartis Ag PHARMACEUTICAL COMPOSITIONS INCLUDING 4-AMINO-5-FLUORO-3- LACTATE MONOHIDRATE [6- (4-METHYL-PIPERAZIN-1-IL) -1H-BENCIMIDAZOL-2-IL] -1H-QUINOLIN-2-ONA, PROCESS FOR THE COMPOSITION PRODUCTION

Also Published As

Publication number Publication date
JP2015505562A (en) 2015-02-23
MX2014009303A (en) 2014-10-14
EP2809312A1 (en) 2014-12-10
BR112014017985A8 (en) 2017-07-11
KR20140117457A (en) 2014-10-07
WO2013116293A1 (en) 2013-08-08
CN104093402A (en) 2014-10-08
AU2013215251A1 (en) 2014-08-14
RU2014135436A (en) 2016-03-27
CA2861377A1 (en) 2013-08-08
BR112014017985A2 (en) 2017-06-20
US20140378422A1 (en) 2014-12-25

Similar Documents

Publication Publication Date Title
IN2014DN05869A (en)
PH12018501807A1 (en) Pyrazolopyrrolidine derivatives and their use in the treatment of diseas
MX2020010151A (en) 1,4-disubstituted pyridazine analogs and methods for treating smn-deficiency-related conditions.
MX2015016344A (en) Imidazopyrrolidinone derivatives and their use in the treatment of disease.
EA201690287A1 (en) 1,4-DESIGNED ANALOGUES OF PYRIDAZIN QUINOLINE AND METHODS OF TREATING CONDITIONS ASSOCIATED WITH SMN-DEFICIENCY
PH12013501341A1 (en) Morphinan compounds
MX2013012588A (en) Kinase inhibitors.
MX2021011563A (en) 2,3-dihydro-isoindole-1-on derivative as btk kinase suppressant, and pharmaceutical composition including same.
EA201391485A1 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES
MD20140059A2 (en) Substituted 4-phenyl-pyridines for the treatment of NK-1 receptor related diseases
EA201101507A1 (en) METHODS OF TREATMENT OF SOLID TUMORS
EA201391263A1 (en) COMBINED THERAPIES OF HEMATOLOGICAL TUMORS
BR112014003237A2 (en) indazole compounds, compositions and methods of use
WO2011127333A3 (en) Compounds for treating disease, for administering, and for pharmaceutical compositions
EA201391486A1 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF PARKINSON'S DISEASE
PH12017501294A1 (en) Compounds, compositions and methods useful for cholesterol mobilisation
MX2015016421A (en) Pyrazolo-pyrrolidin-4-one derivatives as bet inhibitors and their use in the treatment of disease.
BR112013019256A2 (en) il-17 and ifn-gamma inhibition for the treatment of autoimmune inflammation
TN2012000421A1 (en) Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents
CO6630082A2 (en) Lupus nephritis treatment using laquinimod
WO2014070991A3 (en) Galactopyranosyl-cyclohexyl derivatives as e-selectin antagonists
MX2015016425A (en) Pyrazolo-pyrrolidin-4-one derivatives and their use in the treatment of disease.
EA201591175A1 (en) TRICYCLIC COMPOUNDS AS CFTR INHIBITORS
EA201370230A1 (en) NEW ROCK INHIBITORS
EA201490573A1 (en) CONTAINING BENZOTHIAZOLONE